Bavarian Nordic (OTCMKTS:BVNRY) Shares Gap Down – Should You Sell?

Bavarian Nordic (OTCMKTS:BVNRY) shares gapped down prior to trading on Monday . The stock had previously closed at $9.19, but opened at $8.67. Bavarian Nordic shares last traded at $8.67, with a volume of 228 shares changing hands.

Bavarian Nordic Stock Down 4.4%

The business’s 50-day simple moving average is $9.81 and its two-hundred day simple moving average is $9.92. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of 11.55 and a beta of 1.19.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its earnings results on Wednesday, May 13th. The company reported $0.01 EPS for the quarter. Bavarian Nordic had a return on equity of 9.32% and a net margin of 19.74%.The firm had revenue of $165.70 million for the quarter.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.